Hyaluronidase - Halozyme
Alternative Names: Hyaluronidase human injection - Halozyme; Hylenex; HYLENEX® recombinant; rHuPH20Latest Information Update: 11 Jun 2024
Price :
$50 *
At a glance
- Originator Halozyme Therapeutics
- Developer Avid Bioservices
- Class Antineoplastics; Glycoside hydrolases; Polysaccharide lyases
- Mechanism of Action Hyaluronic acid modulators; Hyaluronidase replacements; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Unspecified
Most Recent Events
- 05 Jun 2024 Halozyme Therapeutics has patent protection for Hyaluronidase in European Union
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 03 Jun 2016 Baxalta has been acquired and merged into Shire